6.28
-0.23(-3.53%)
Currency In USD
| Previous Close | 6.51 |
| Open | 6.42 |
| Day High | 6.55 |
| Day Low | 6.23 |
| 52-Week High | 11 |
| 52-Week Low | 3.71 |
| Volume | 345,140 |
| Average Volume | 488,631 |
| Market Cap | 134.97M |
| PE | -1.83 |
| EPS | -3.44 |
| Moving Average 50 Days | 6.23 |
| Moving Average 200 Days | 5.4 |
| Change | -0.23 |
If you invested $1000 in Unicycive Therapeutics, Inc. (UNCY) since IPO date, it would be worth $125.6 as of February 21, 2026 at a share price of $6.28. Whereas If you bought $1000 worth of Unicycive Therapeutics, Inc. (UNCY) shares 3 years ago, it would be worth $1,184.91 as of February 21, 2026 at a share price of $6.28.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim’s Emerging Outlook: Biotech Summit
GlobeNewswire Inc.
Feb 04, 2026 12:05 PM GMT
LOS ALTOS, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shal
UPDATE - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission
GlobeNewswire Inc.
Jan 29, 2026 2:15 PM GMT
FDA assigns Prescription Drug User Fee Act (PDUFA) target date of June 29, 2026Ended 2025 with unaudited cash position of $41.3M with expected runway into 2027 LOS ALTOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unic
Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission
GlobeNewswire Inc.
Jan 29, 2026 12:05 PM GMT
DA assigns Prescription Drug User Fee Act (PDUFA) target date of June 27, 2026Ended 2025 with unaudited cash position of $41.3M with expected runway into 2027 LOS ALTOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicy